BTIG analyst Mark Massaro reiterated a Buy rating on Exagen (XGN – Research Report) yesterday and set a price target of $5.00. The company’s shares closed yesterday at $2.30.
Massaro covers the Healthcare sector, focusing on stocks such as BioNano Genomics, Cerus, and CareDx. According to TipRanks, Massaro has an average return of -3.8% and a 40.12% success rate on recommended stocks.
The analyst consensus on Exagen is currently a Hold rating.
See today’s best-performing stocks on TipRanks >>
XGN market cap is currently $38.35M and has a P/E ratio of -1.00.
Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of XGN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Exagen Diagnostics Inc was incorporated under the laws of the state of New Mexico in 2002. The Company is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets four products under its Avise brand to provide an accurate, timely and differential diagnosis and to optimize the treatment of ARDs. It processed approximately 9,300 patient specimens for its diagnostic product line, Avise SLE. It markets and sells solutions to community rheumatologists.
Read More on XGN:
- Exagen Inc. Reports Fourth Quarter and Full Year 2022 Results
- Exagen Inc. to Participate in Upcoming March Conferences
- Exagen Inc. to Participate in the 2023 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
- Exagen elects Nova as Executive Chair of board of directors
- Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors
